Organon & Co. (NYSE:OGN) Sets New 52-Week Low – Time to Sell?

Organon & Co. (NYSE:OGN)’s share price hit a new 52-week low during trading on Wednesday . The company traded as low as $6.16 and last traded at $6.2150, with a volume of 620723 shares. The stock had previously closed at $6.39.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on the company. Wall Street Zen lowered Organon & Co. from a “buy” rating to a “hold” rating in a report on Saturday, January 31st. Zacks Research lowered shares of Organon & Co. from a “hold” rating to a “strong sell” rating in a research note on Thursday, January 29th. Finally, Barclays boosted their price objective on shares of Organon & Co. from $7.50 to $8.00 and gave the company an “underweight” rating in a research report on Tuesday, February 24th. One analyst has rated the stock with a Strong Buy rating, one has issued a Hold rating and five have assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Reduce” and an average price target of $8.50.

Organon & Co. Stock Performance

The stock has a market cap of $1.63 billion, a P/E ratio of 8.84, a PEG ratio of 0.57 and a beta of 0.60. The business has a 50 day moving average price of $7.76 and a 200 day moving average price of $8.21. The company has a quick ratio of 1.23, a current ratio of 1.82 and a debt-to-equity ratio of 11.47.

Organon & Co. (NYSE:OGN) last issued its quarterly earnings results on Thursday, February 12th. The company reported $0.63 earnings per share for the quarter, missing the consensus estimate of $0.73 by ($0.10). Organon & Co. had a return on equity of 122.01% and a net margin of 3.01%.The business had revenue of $1.51 billion during the quarter, compared to analysts’ expectations of $1.52 billion. During the same quarter in the previous year, the company posted $0.90 earnings per share. The company’s quarterly revenue was down 5.3% compared to the same quarter last year. As a group, sell-side analysts expect that Organon & Co. will post 3.68 EPS for the current year.

Organon & Co. Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Thursday, March 12th. Stockholders of record on Monday, February 23rd were given a dividend of $0.02 per share. This represents a $0.08 annualized dividend and a dividend yield of 1.3%. The ex-dividend date was Monday, February 23rd. Organon & Co.’s dividend payout ratio (DPR) is 11.27%.

Institutional Trading of Organon & Co.

Large investors have recently made changes to their positions in the stock. AQR Capital Management LLC lifted its holdings in Organon & Co. by 105.2% during the 4th quarter. AQR Capital Management LLC now owns 8,570,958 shares of the company’s stock valued at $61,282,000 after buying an additional 4,394,814 shares in the last quarter. Vanguard Group Inc. boosted its position in Organon & Co. by 11.3% in the 3rd quarter. Vanguard Group Inc. now owns 35,928,403 shares of the company’s stock valued at $383,715,000 after buying an additional 3,650,860 shares during the period. Norges Bank bought a new position in Organon & Co. in the 2nd quarter worth about $19,778,000. UBS Group AG grew its stake in Organon & Co. by 55.2% in the 4th quarter. UBS Group AG now owns 4,295,002 shares of the company’s stock worth $30,795,000 after acquiring an additional 1,527,492 shares in the last quarter. Finally, Private Management Group Inc. increased its position in shares of Organon & Co. by 38.3% during the fourth quarter. Private Management Group Inc. now owns 4,347,073 shares of the company’s stock worth $31,169,000 after acquiring an additional 1,204,979 shares during the period. 77.43% of the stock is owned by hedge funds and other institutional investors.

Organon & Co. Company Profile

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.